GlassScriptPhysician profile
Paul L Weinstein
NPI 1457446718
$288,128.52
in general payments reported to CMS, 2019-2025
17 companies · $629 in 2025
The $629 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126K · 2020: $26K · 2021: $60K · 2022: $46K · 2023: $20K · 2024: $8,887 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Consulting Fee: $8,883 · Travel and Lodging: $3,690 · Food and Beverage: $521 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,765.00 |
| Consulting Fee | $8,883.00 |
| Travel and Lodging | $3,690.47 |
| Food and Beverage | $520.76 |
| Education | $107.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $122,789.68 | 2019-2025 | Lumakras |
| Lilly USA, LLC | $117,497.79 | 2019-2023 | Retevmo |
| Ipsen Biopharmaceuticals, INC | $23,902.27 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $6,982.50 | 2019-2024 | Imfinzi |
| Pfizer INC. | $3,497.55 | 2019 | |
| Celgene Corporation | $3,288.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $2,150.00 | 2019-2023 | Piqray |
| Genentech USA, INC. | $2,073.44 | 2019 | |
| Seagen INC. | $1,750.00 | 2023 | Tukysa |
| G1 Therapeutics, INC. | $1,594.01 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,189.80 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $655.50 | 2023 | |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Merck Sharp & Dohme LLC | $113.79 | 2019-2025 | Welireg |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $81.99 | 2023 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.